KDR and hepatocellular carcinoma: In a mouse model of hepatocellular carcinoma, vascular normalization induced by tyrosin-kinase inhibitors of the vascular endothelial growth factor receptor-2 (VEGFR2) antibody can enhance the effectiveness of ICIs by reshaping the immune microenvironment [78].